Company logo

ATNF - 180 Life Sciences Corp.

NASDAQ -> Healthcare -> Biotechnology
Palo Alto, United States
Type: Equity

ATNF price evolution
ATNF
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Current assets
Cash $0.68 $1.98 $2.66 $2.01
Short term investments
Net receivables $0.01 $0.45 $0.1 $0.09
Inventory
Total current assets $1.85 $3.64 $3.37 $2.93
Long term investments
Property, plant & equipment
Goodwill & intangible assets $1.59 $1.62 $1.59 $1.67
Total noncurrent assets $1.59 $1.62 $1.59 $10.73
Total investments
Total assets $3.44 $5.26 $4.96 $13.67
Current liabilities
Accounts payable $1.84 $2.16 $1.76 $0.89
Deferred revenue
Short long term debt $0.77 $1.03 $0.33 $0.59
Total current liabilities $4.08 $5.06 $4.81 $4.27
Long term debt $0.02 $0.02 $0.02 $0.03
Total noncurrent liabilities $0.32 $0.32 $0.3 $2.68
Total debt $0.79 $1.05 $0.36 $0.61
Total liabilities $4.4 $5.39 $5.11 $6.95
Shareholders' equity
Retained earnings -$128.41 -$127.34 -$126.12 -$115.85
Other shareholder equity -$2.89 -$2.9 -$2.85 -$2.9
Total shareholder equity -$0.95 -$0.13 -$0.15 $6.72
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $1.98 $6.97 $8.22 $2.11
Short term investments
Net receivables $0.45 $0.62 $0.69 $0.3
Inventory
Total current assets $3.64 $8.93 $11.2 $4.01
Long term investments
Property, plant & equipment
Goodwill & intangible assets $1.62 $1.66 $38.94 $38.95
Total noncurrent assets $1.62 $10.72 $51.51 $51.52
Total investments
Total assets $5.26 $19.65 $62.71 $55.53
Current liabilities
Accounts payable $2.16 $1.8 $0.59 $8.74
Deferred revenue
Short long term debt $1.03 $1.31 $1.91 $3.67
Total current liabilities $5.06 $5.66 $19.7 $21.42
Long term debt $0.02 $0.03 $0.05 $0.11
Total noncurrent liabilities $0.32 $2.65 $3.69 $3.83
Total debt $1.05 $1.34 $1.96 $3.78
Total liabilities $5.39 $8.31 $23.39 $25.25
Shareholders' equity
Retained earnings -$127.34 -$107.41 -$68.68 -$48.36
Other shareholder equity -$2.9 -$2.89 $0.82 $0.64
Total shareholder equity -$0.13 $11.34 $39.32 $30.29
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $0.54 -$0.04 $1.1 $0.92
Selling, general & administrative $1.56 $1.49 $2.43 $2.76
Total operating expenses $2.09 $1.45 $3.54 $3.68
Operating income -$2.09 -$1.45 -$3.54 -$3.68
Income from continuing operations
EBIT -$1.05 -$1.22 -$12.6 -$3.67
Income tax expense -$0 -$2.35
Interest expense $0.02 $0.01 $0.01 $0.01
Net income
Net income -$1.07 -$1.23 -$10.27 -$3.68
Income (for common shares) -$1.07 -$1.23 -$10.27 -$3.68
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $2.78 $2.43 $3.95 $2.29
Selling, general & administrative $10.69 $15.47 $11.69 $3.36
Total operating expenses $13.48 $17.9 $15.64 $5.65
Operating income -$13.48 -$17.9 -$15.64 -$5.65
Income from continuing operations
EBIT -$22.24 -$39.64 -$20.16 -$9.82
Income tax expense -$2.35 -$0.94 -$0.02 -$0.02
Interest expense $0.04 $0.03 $0.19 $1.09
Net income
Net income -$19.94 -$38.73 -$20.32 -$10.88
Income (for common shares) -$19.94 -$38.73 -$20.32 -$12.01
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Net income -$1.07 -$1.23 -$10.27 -$3.68
Operating activities
Depreciation $0.02 $0.02 $0.03 $0.03
Business acquisitions & disposals
Stock-based compensation $0.24 $0.5 $0.58 $0.55
Total cash flows from operations -$1.03 -$2.16 -$1.78 -$3.12
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $0.83 $2.7 $2.72
Net borrowings -$0.26 $0.7 -$0.26 -$0.26
Total cash flows from financing -$0.26 $1.47 $2.45 $2.46
Effect of exchange rate -$0 $0 -$0.02 $0.02
Change in cash and equivalents -$1.3 -$0.69 $0.65 -$0.64
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$19.94 -$38.73 -$20.32 -$10.88
Operating activities
Depreciation $0.11 $0.11 $0.11 $0.13
Business acquisitions & disposals $3.01
Stock-based compensation $2.19 $2.63 $2.85 $1.12
Total cash flows from operations -$10.92 -$12.13 -$19.37 -$3.87
Investing activities
Capital expenditures
Investments $11.48
Total cash flows from investing $14.49
Financing activities
Dividends paid
Sale and purchase of stock $6.26 $11.48 $24.61 -$8.93
Net borrowings -$0.29 -$0.61 $0.8 $0.2
Total cash flows from financing $5.91 $10.87 $25.41 -$8.73
Effect of exchange rate $0.02 -$0 $0.08 $0.14
Change in cash and equivalents -$4.99 -$1.25 $6.12 $2.03
Fundamentals
Market cap $1.97M
Enterprise value $2.08M
Shares outstanding 853.00K
Revenue $0.00
EBITDA -$18.43M
EBIT -$18.54M
Net Income -$16.24M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -0.12
EV/Sales N/A
EV/EBITDA -0.11
EV/EBIT -0.11
P/S ratio N/A
P/B ratio 1.02
Book/Share 2.27
Cash/Share 0.79
EPS -$19.04
ROA -237.76%
ROE -1.18K%
Debt/Equity -42.18
Net debt/EBITDA -0.20
Current ratio 0.45
Quick ratio 0.45